Platelet glycoprotein IIb/IIIa inhibitors during percutaneous coronary interventions: a pharmacological and clinical review

Bibliography

• FURIE B, FURIE BC: Molecular and cellular biology of blood coagulation.N Engl. J. Med. (1992) 326:800–806.
   PubMed Web of Science ®Google Scholar
• SCHWARTZ L, BOURASSA MG, LESPERANCE J et al.: Aspirin and dipyridamole in the prevention of restenosis after percutaneous transluminal coronary angioplasty. N Engl. I Med. (1988) 318:1714–1719.
   PubMed Web of Science ®Google Scholar
• SAVAGE MP, GOLDBERG S, BOVE AAet al.: Effect of thromboxane A2 blockade on clinical outcome and restenosis after successful coronary angioplasty: Multi-Hospital Eastern Atlantic Restenosis Trail(M-HEART II). Circulation (1995) 93:3194–3200.
   Google Scholar
• FLATHER MD, VVEITZ JI, YUSUF S et al.: Reactivation of coagulation after stopping infusions of recombinant hirudin and unfractionated heparin in unstable angina and myocardial infarction without ST elevation: results of a randomized trial. OASIS Pilot Study Investigators. Eur: Heart J. (2000) 21:1473–1481.
   Google Scholar
• SCHOMIG A, NEUMANN FJ, KASTRATI A et al.: A randomized comparison of antiplatelet and anticoagulant therapy after placement of coronary-artery stents. N Engl. J. Med.(1996) 334:1084–1089.
   PubMed Web of Science ®Google Scholar
• HALL P, NAKAMURA S, MAIELLO L et al.: A randomized comparison of ticlopidine and aspirin therapy versus aspirin alone after successful intravascular ultrasound guided stent implantation.Circulation (1996) 93:215–222.
   PubMed Web of Science ®Google Scholar
• URBAN P, MACAYA C, RUPPRECHT H et al.: randomized evaluation of anticoagulation versus antiplatelet therapy after coronary stent implantation in high risk-patients: the Multicenter Aspirin andTiclopidine Trial after Intracoronary Stenting (MATTIS). Circulation (1998) 98:2126–2132.
   PubMed Web of Science ®Google Scholar
• LEON M, BAIM D, POPMA J et al.: A clinical trial comparing three antithrombotic drug regimens after coronary artery stenting. N Engl. J. Med. (1998) 339:1671–1678.
   Google Scholar
• MEHTA SR, YUSUF S, PETERS RJG et al., on behalf of the CURE Investigators: Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary interventions: the PCI-CURE study. Lancet (2001) 358:527–33.
   PubMed Web of Science ®Google Scholar
• STEINHUBL SR, BERGER PB, MANN JT 3' et al.: CREDO Investigators: Clopidogrel for the Reduction of Events During Observation. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. JAMA (2002) 288:2411–2420.
   Google Scholar
• NO AUTHORS LISTED: Randomized placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina: the CAPTURE study. Lancet (1997) 349:1429-1435 [Erratum in: Lancet (1997) 350(9079):7441.
   Google Scholar
• TOPOL EJ, CALIFF RIVI, WEISMAN HF et al.: Randomized trial of coronary intervention with antibody against platelet IIb/IIIa integrin for reduction of clinical restenosis: results at six months. The EPIC Investigators. Lancet (1994) 343:881–886.
   PubMedGoogle Scholar
• THE EPILOG INVESTIGATORS: Platelet glycoprotein IIb/IIIa receptor blockade and low dose heparin during percutaneous coronary revascularization.N Engl. J. Med. (1997) 336: 1689-1696.
   Google Scholar
• LINCOFF AM, CALIFF RM,MOLITERNO DJ et al: Complementary clinical benefits of coronary-artery stenting and blockade of glycoprotein IIb/IIIa receptors. Evaluation of Platelet IIb/IIIa Inhibition in Stenting Investigators.N. Engl. J. Med. (1999) 341:319–327.
   Google Scholar
• NO AUTHORS LISTED: Randomizedaplacebo-controlled trial of effect of eptifibatide on complications of percutaneous coronary intervention: IMPACT-II. Integrelin to Minimise Platelet Aggregation and Coronary Thrombosis-II.Lancet (1997) 349:1422–1428.
   Google Scholar
• THE RESTORE INVESTIGATORS: Randomized Efficacy Study of Tirofiban for Outcomes and REstenosis. Effect of Platelet glycoprotein IIb/IIIa blockade with tirofiban on adverse cardiac events in patients with unstable angina or acute myocardial infarction undergoing coronary angioplasty. Circulation (1997) 96:1445–1453.
   Google Scholar
• THE EPISTENT INVESTIGATORS: Randomized placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa receptor blockade. Lancet (1998) 352:87–92.
   PubMed Web of Science ®Google Scholar
• THE ESPRIT INVESTIGATORS: Novel dosing regimen of eptifibatide in planned coronary stent implantation (ESPRIT): a randomized, placebo-controlled trial.aLancet (2000) 256:2037–2044.
   Google Scholar
• TOPOL E, MOLITERNO D,HERRMANN H et al.: Comparison of two platelet glycoprotein-IIb/Illa inhibitors, tirofiban and abciximab, for the prevention of ischemic events with percutaneous coronary revascularization.aN. Engl. J. Med. (2001) 344:1888-1894.a345
   Google Scholar
• GOGSTAD GO, BROSSTAD F, KRUTNES MB, HAGEN I, SOLUM NO: Fibrinogen binding properties of the human platelet glycoprotein-IIb/IIIa complex: a study using crossed- radio-immuno-electrophoresis. Blood (1982) 60:663–671.
   PubMed Web of Science ®Google Scholar
• PLOW EF, GINSBERG MH: GP IIb-IIIa as a prototypic adhesion receptor.Frog. Hemost. Thromb. (1989) 9:117–156.
   PubMedGoogle Scholar
• PLOW EF, GINSBERG MH: Specific and saturable binding of plasma fibronectin to thrombin-stimulated platelets.Biol. Chem. (1981) 256:9477–9482.
   Google Scholar
• PLOW EF, MC EVER RP, COLLER BS, WOODS VL Jr, MAGUERIE GA, GINSBERG MH: Related binding mechanisms for fibrinogen, fibronectin, von Willebrand factor, and thrombospondin on thrombin-stimulated human platelets. Blood (1985) 66:724–727.
   PubMed Web of Science ®Google Scholar
• PHILLIPS DR, CHARO IF, PARISE LV, FITZGERALD LA: The platelet membrane glycoprotein-IIb/IIIa complex. Blood(1988) 71:831–843.
   PubMed Web of Science ®Google Scholar
• PIERSCHBACHER MD, RUOSLAHTI E: Cell attachment activity of fibronectin can be duplicated by small synthetic fragments of the molecule. Nature (1984) 309:30–33.
   PubMed Web of Science ®Google Scholar
• KLOCZEWIAK M, TIMMONS S, HAWIGER J: Recognition site of the platelet receptor is present on the 15-residue carboxy-terminal fragment of the 7 chain of human fibrinogen and is not involved in the fibrin polymerization reaction.Thromb. Res. (1983) 29:249–255.
   PubMed Web of Science ®Google Scholar
• PLOW EF, D'SOUZA SE,aGINSBERG MH: Ligand binding to GP IIb-IIIa: a status report. Semin. Thromb. Hemost. (1992) 18:324–332.
   PubMedGoogle Scholar
• COLLER BS, PEERSCHKE El, SOUDDER LE, SULLIVAN CA: A murine monoclonal antibody that completely blocks the binding of fibrinogen to platelets produces a thrombasthenic-like state in normal platelets and binds to glycoprotein IIb and or IIIa.Clin. Invest. (1983) 72:325–338.
   Google Scholar
• KLEIMAN NS, RAIZNER AE,aJORDAN R et al.: Differential inhibition of platelet aggregation induced by adenosine diphosphate or a thrombin receptor-activating peptide in patients treated with bolus chimeric c7E3 Fab: implications for inhibition of the internal pool ofGP IIb/IIIa receptors. J. Am. Coll. Cardiol(1995) 26:1665–1671.
   Google Scholar
• MASCELLI MA, LANCE ET, DAMARAJU L et al.: Pharmacodynamic profile of short-term abciximab treatment demonstrates prolonged platelet inhibition with gradual recovery of glycoprotein IIb/IIIa receptor blockade.Circulation (1998) 97:1680–1688.
   Google Scholar
• HARRINGTON RA, KLEIMAN NS, KOTTKE-MARCHAUT K et al.: Immediate and reversible platelet inhibition of intravenous administration of a peptide glycoprotein IIb/IIIa inhibitor during percutaneous coronary intervention. Am.j Cardiol (1995) 76:1222–1227.
   PubMed Web of Science ®Google Scholar
• KEREIAKES DJ, KLEIMAN NS, AMBROSE J et al.: Randomized, double blind, placebo-controlled dose-ranging study of tirofiban (MK-383) platelet IIb/IIIa blockade in high risk patients undergoing coronary angioplasty. J. Am. Coll. Cardiol (1996) 27:536–542.
   PubMed Web of Science ®Google Scholar
• ALIG L, EDENHOFER A, HAD VARY P et al.: Low molecular weight, non peptide fibrinogen receptor antagonists. Med. Chem. (1992) 35:4393–4407.
   Google Scholar
• TCHENG JE, ELLIS SG, GEORGE BS et al.: Pharmacodynamics of chimeric glycoprotein IIb/IIIa integrin antiplatelet antibody fab 7e3 in high-risk coronary angioplasty. Circulation (1994) 90: 1757-1764.
   Google Scholar
• GRUBERG L, LANSKY AJ, DANGAS G, STONE GW: Glycoprotein IIb/IIIa inhibitors during primary angioplasty for acute myocardial infarction. Carr. Interv. Cardiol Rep. (1999) 1:359–367.
   PubMedGoogle Scholar
• GRINES CL, BROWNE KF, MARCO J et al: A comparison of immediate angioplasty with thrombolytic therapy for acute myocardial infarction. The Primary Angioplasty in Myocardial Infarction Study group. N Engl. J. Med. (1993) 328:673–679.
   Google Scholar
• GIBBONS RJ, HOLMES DR,REEDER GS, BAILEY KR,HOPFENSPIRGER MR, GERSH BJ: Immediate angioplasty compared with the administration of a thrombolytic agent followed by conservative treatment for myocardial infarction. The Mayo Coronary care Unit and Catheterization Laboratory Groups. N Engl. J. Med. (1993) 328:685–691.
   Google Scholar
• RODRIGUEZ A, BERNARDI V, FERNANDEZ M et al.: In-hospital and late results of coronary stents versus conventional balloon angioplasty in acute myocardial infarction (GRAMI Gianturco-Roubin in Acute MycardialInfarction. Am. J. Cardiol (1998) 81:1286–1291.
   PubMedGoogle Scholar
• MAILLARD L, HAMON M, KHALIFE K et al.: A comparison of systemic stenting and conventional balloon angioplasty durin primary percutaneous transluminal coronary angioplasty for acute myocardial infarction. STENTIM-2 Investigators. J. Am. Coll. Cardiol (2000) 35:1729–1736.
   Google Scholar
• STONE GW, BRODIE BR, GRIFFIN JJ et al.: Clinical and angiographic follow-up after Primary stenting in Acute Myocardial Infarction (PAMI) stent pilot trial. Circulation (1999) 99:1548–1554.
   PubMed Web of Science ®Google Scholar
• STONE GW, LANSKY AJ, MEHRAN R et al.: Beyond TIMI-3 flow: the importance of restored myocardial perfusion for survival in high risk patients undergoing primary or rescue PTCA. J. Am. Coll. Cardiol (2000) 35(Suppl. A):403A (Abstract).
   Google Scholar
• BRENER SJ, BARR LA,BURCHENAL JEB et al. on behalf of the RAPPORT Investigators: Radomized, placebo controlled trial of platelet glycoprotein IIb/IIIa blockade with primary angioplasty for acute myocardial infarction. Circulation (1998) 98:734–741.
   Google Scholar
• AZAR RR, MCKAY RG, THOMPSON PD et al: Abciximab in primary coronary angioplasty for acute myocardial infarction improves short-and medium-term outcomes. J. Am. Coll. Cardiol (1998) 32:1996–2002.
   PubMedGoogle Scholar
• VAN DEN MERKHOF LFM, ZIJLSTRA F, OLSSON H et al.: Abciximab in the treatment of acute myocardial infarction eligible for primary percutaneous transluminal coronary angioplasty. Results of the glycoprotein receptor antagonist patency evaluation (GRAPE) Pilot Study. J. AM. Coll. Cardiol (1999) 33:1528–1532.
   Google Scholar
• MONTALESCOT G, BARRAGAN P, WITTENBERG 0 et al.: Platelet glycoprotein IIb/IIIa inhibitors with coronary stenting for Acute Myocardial Infarction. N Engl. J. Med. (2001) 344:1895–1903.
   Google Scholar
• NEUMANN FJ, KASTRATI A, SCHMITT C et al.: Effect of glycoprotein IIb/IIIa receptor blockade with abciximab on clinical and angiographic restenosis rate after the placement of coronary stents following acute myocardial infarction. J. Am. Coll. Cardiol (2000) 35:915–921.
   PubMed Web of Science ®Google Scholar
• THE CADILLAC INVESTIGATORS: Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complication (CADILLAC) trial. N Engl. J. Med. (2002) 346:957–966.
   PubMedGoogle Scholar
• CUTUP DE, COVE CJ, IRONS D et al:Emergency room administration of eptifibatide before primary angioplasty for ST elevation acute myocardial infarction and its effect on baseline coronary flow and procedure outcomes. Am. J. Cardiol (2001) 88:A6:62–64.
   Google Scholar
• LEE DP, HERITY NA, HIATT BL et al. TIrofiban Given in the Emergency Room before Primary Angioplasty: Adjunctive platelet glycoprotein IIb/IIIa receptor inhibition with tirofiban before primary angioplasty improves angiographic outcomes: results of the TIrofiban Given in the Emergency Room before Primary Angioplasty (TIGER-PA) Pilot Trial. Circulation (2003) 107:1497–1501.
   PubMed Web of Science ®Google Scholar
• MILLER JM, SMALLING R, OHMAN M et al. for the GUSTO-III Investigators: Effectiveness of early coronary angioplasty and abciximab for failed thrombolysis (reteplase or alteplase) during acute myocardial infarction (results of the GUSTO-III Trial). Am. Cardiol (1999) 84:779–784.
   PubMed Web of Science ®Google Scholar
• PRISM-PLUS STUDYINVESTIGATORS: Inhibition of platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q wave myocardial infarction. N Engl. I Med. (1998) 338:1488–1497.
   PubMedGoogle Scholar
• BOERSMA E, AKKERHUIS KM, THEROUX P, CALIFF RM, TOPOL EJ, SIMOONS ML: Platelet glycoprotein IIb/IIIa receptor inhibition in non-ST-elevation acute coronary syndromes: early benefit during medical treatment only, with additional protection during percutaneous coronary intervention. Circulation (1999) 100:2045–2048.
   PubMed Web of Science ®Google Scholar
• NO AUTHORS LISTED: Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes. The PURSUIT trial Investigators. Platelet glycoprotein IIb/IIIa in unstable angina; receptor suppression using integrilin treatment. N Engl. I Med. (1998) 339:436–443.
   Google Scholar
• O'SHEA JC, BULLER CE, CANTOR WJ et al. on behalf of the ESPRIT Investigators: Long-term efficacy of platelet glycoprotein IIb/IIIa integrin blockade with eptifibatide in coronary stent intervention.JAMA (2002) 287:618–621.
   Google Scholar
• SULEIMAN M, GRUBERG L, HAMMERMAN H et al.: Comparison of two platelet glycoprotein IIb/IIIa inhibitors, eptifibatide and abciximab: outcomes,complications and thrombocytopenia during percutaneous coronary intervention..1 Invas. Cardiol (2003) 15:319–323.
   Google Scholar
• THE ERASER INVESTIGATORS: Acute platelet inhibition with abciximab does not reduce in-stent restenosis (ERASER study). Circulation (1999) 100:799–806.
   PubMed Web of Science ®Google Scholar
• MANSO SP, LINCOFF AM, ELLIS G et al.: Optimizing the percutaneous interventional outcomes for patients with diabetes mellitus: results of EPISTENT (Evaluation of Platelet IIb/IIIa Inhibition for Stenting Trial) diabetic substudy. Circulation (1999) 100:2477–2484.
   PubMedGoogle Scholar
• ROFFI M, MOLITERNO D, MEIER B et al.: Impact of different platelet glycoprotein IIb/IIIa receptor inhibitors among diabetic patients undergoing percutaneous intervention: Do Tirofiban and ReoPro Give similar Efficacy outcomes Trial (TARGET) 1-year follow-up. Circulation (2002) 105:2730–2736.
   PubMed Web of Science ®Google Scholar
• BRENER SJ, ELLIS SG, SCHNEIDER TOPOL EJ: Frequency and long-term impact of myonecrosis after coronary stenting. Eur: Heart I. (2002) 23:869–876.
   PubMed Web of Science ®Google Scholar
• ADGEY AA, MATHEW TP,HARBINSON MT: Periprocedural creatine kinase-MB elevations: long-term impact and clinical implications. Clin. Cardiol (1999) 22:257–265.
   PubMedGoogle Scholar
• ISLAM MA, BLANKENSHIP JC, BALOG C et al.: Effect of abciximab on angiographic complications during percutaneous coronary stenting in the Evaluation of Platelet IIb/IIIa inhibition in Stenting Trial (EPISTENT). Am. I Cardiol (2002) 90:916–921.
   PubMedGoogle Scholar
• BLANKENSHIP JC, TASISSA G, O'SHEA JC et al.: Effect of glycoprotein IIb/IIIa receptor inhibition on angiographic complications during percutaneous coronary stenting in the ESPRIT trial. J. Am. Coll Cardiol (2001) 38:653–658.
   Google Scholar
• BLANKENSHIP JC, SIGMON KN, PIEPER KS: Effect of eptifibatide on angiographic complications during percutaneous coronary stenting in the IMPACT- (Integrilin to Minimise Platelet Aggregation and Coronary Thrombosis) II Trial. Am.! Cardiol (2001) 88:969–973.
   PubMedGoogle Scholar
• TARDIFF BE, CALIFF RM, TCHENG JE et al.: Clinical outcomes after detection of elevated cardiac enzymes in patients undergoing percutaneous coronary intervention. IMPACT-II Investigators. Integrelin (eptifibatide) to Minimise PlateletaAggregation and Coronary Thrombosis II.aJ. Am. Coll. Cardiol (1999) 33:88–96.
   Google Scholar
• ANDERSON KM, CALIFF RM, STONE GW et al.: Long-term mortality benefit with abciximab in patients undergoing percutaneous coronary intervention. I Am. Coll Cardiol (2001) 37:2059–2065.
   PubMed Web of Science ®Google Scholar
• MANDAK JS, BLANKENSHIP JC, GARDNER LH et al.: Modifiable risk factors for vascular access site complications in the IMPACT-II Trial of angioplasty with versus without eptifibatide. Integrilin to Minimize Platelet Aggregation and Coronary Thrombosis. I Am. Coll. Cardiol (1998) 31:1518–1524.
   PubMed Web of Science ®Google Scholar
• AGUIRRE FU, TOPOL EJ,FERGUSON JJ et al.: Bleeding complications with the chimeric antibody to platelet glycoprotein IIb/IIIa- integrin in patients undergoing percutaneous coronary intervention. EPIC Investigators. Circulation (1995) 91:2882–2890.
   Google Scholar
• BLANKENSHIP JC, HELLKAMP AS, AGUIRRE FU et al.: Vascular access site complication after percutaneous coronary intervention with abciximab in the Evaluation of c7EC for the Prevention of Ischemic Complications (EPIC) trial. kn. Cardiol (1998) 81:36–40.
   Google Scholar
• KEREIAKES DJ, GRINES C, FRY E: Enoxaparin and abciximab adjunctive pharmacotherapy during percutaneous coronary intervention. Invasive Cardiol (2001) 13:272–278.
   PubMedGoogle Scholar
• CALIFF RM: Combination therapy for acute myocardial infarction: fibrinolytic therapy and glycoprotein IIb/IIIa inhibition. Am. Heart! (2000) 139:S33–S37.
   Google Scholar
• LINCOFF AM, CALIFF RM, VAN DE VVERF F et al. Global Use of Strategies To Open Coronary Arteries Investigators (GUSTO): Mortality at 1 year with combination platelet glycoprotein IIb/IIIa inhibition and reduced-dose fibrinolytic therapy versus conventional fibrinolytic therapy for acute myocardial infarction: GUSTO V randomized trial. JAMA (2002) 288:2130–2135.
   Google Scholar
• ANTMAN EM, GIBSON CM, DE LEMOS JA et al. on behalf of The Thrombolysis in Myocardial Infarction (TIMI) 14 Investigators: Combination reperfusion therapy with abciximab and reduced dose reteplase: results from TIMI 14. Ear. Heart J. (2000) 23:1944–1953.
   Google Scholar
• BERKOWITZ SD, HARRINTON RA, RUND MM et al.: Acute profound thrombocytopenia after c7E3 Fab (abciximab) therapy. Circulation (1997) 95:809–813.
   PubMed Web of Science ®Google Scholar
• DASGUPTA H, BLANKENSHIP JC, WOOD GC et al.: Thrombocytopenia complicating treatment with intravenous glycoprotein IIb/IIIa receptor inhibitors: a pooled analysis. Am. Heart" (2000) 140:206–211.
   Google Scholar
• HONGO RH, BRENT BN: Association ofeptifibatide and acute profoundathrombocytopenia. Am. ". aCardiol (2001) 88:428–431.
   PubMedGoogle Scholar
• JUERGENE CP, YEUNG AC, OESTERLE SN: Routine platelet transfusion in patients undergoing emergency coronary bypass surgery after receiving abciximab. Am. Cardiol (1997) 80:74–75.
   PubMedGoogle Scholar
• TCHENG JE, KEREIAKES DJ, BRADEN GA et al.: safety of abciximab retreatment- final clinical report of the ReoPro Readministration Registry (R3). Circulation (1998) 98:1-17 (Abstract).
   Google Scholar